In Brief: Cytel
This article was originally published in The Tan Sheet
Executive Summary
Cytel: Reaches milestone in Abbott project to develop manufacturing processes to provide carbohydrates for use in Abbott nutritional products, triggering a $1.5 mil. payment to San Diego-based Cytel. With achievement of the milestone, the technology is being transferred to Abbott for use by its Ross Products division. Cytel's proprietary technology, for enzymatic sugar nucleotide cycling is dubbed SNC Technology. SNC makes large-scale, economic production of bioactive carbohydrates commercially viable, Cytel says. The company is pursuing other collaborations for therapeutic medical and consumer products through its new Glycotechnology business unit. In addition to Abbott, Cytel established a collaboration with the Nextran unit of Baxter last year..